Icagen's lead asthma drug fails in Phase IIa trial
This article was originally published in Scrip
Executive Summary
Icagen is dropping one of its lead drug candidates, senicapoc, after the drug failed to show efficacy in asthma patients in the second of two Phase IIa trials. The US company's share price was down 35%, to $0.49, in pre-market trading on Nasdaq on October 27th.